COMPASS Pathways plc (NASDAQ:CMPS) Sees Significant Increase in Short Interest

COMPASS Pathways plc (NASDAQ:CMPS) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 3,610,000 shares, an increase of 5.6% from the May 15th total of 3,420,000 shares. Based on an average daily trading volume, of 525,000 shares, the days-to-cover ratio is currently 6.9 days.

COMPASS Pathways Stock Performance

CMPS opened at $6.43 on Thursday. The firm has a market capitalization of $439.68 million, a PE ratio of -2.71 and a beta of 2.32. COMPASS Pathways has a twelve month low of $5.01 and a twelve month high of $12.75. The firm’s 50-day moving average price is $7.86 and its 200 day moving average price is $8.90. The company has a current ratio of 15.23, a quick ratio of 15.23 and a debt-to-equity ratio of 0.12.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.03). As a group, sell-side analysts expect that COMPASS Pathways will post -2.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CMPS. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research report on Tuesday, April 30th. Morgan Stanley began coverage on shares of COMPASS Pathways in a research report on Monday, April 1st. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of COMPASS Pathways in a research report on Monday, May 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways presently has an average rating of “Buy” and a consensus target price of $47.40.

Insider Activity at COMPASS Pathways

In related news, major shareholder George Jay Goldsmith sold 25,750 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $8.96, for a total transaction of $230,720.00. Following the sale, the insider now owns 4,010,404 shares in the company, valued at $35,933,219.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 85,002 shares of company stock worth $736,921. 4.25% of the stock is owned by company insiders.

Hedge Funds Weigh In On COMPASS Pathways

A number of institutional investors have recently bought and sold shares of CMPS. Quest Partners LLC purchased a new position in COMPASS Pathways during the fourth quarter worth about $33,000. Conservest Capital Advisors Inc. purchased a new position in COMPASS Pathways during the fourth quarter worth about $91,000. TAP Consulting LLC raised its stake in COMPASS Pathways by 14.7% during the third quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock worth $95,000 after purchasing an additional 1,645 shares during the period. EWA LLC purchased a new position in COMPASS Pathways during the fourth quarter worth about $107,000. Finally, Kennedy Capital Management LLC purchased a new position in COMPASS Pathways during the first quarter worth about $139,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.